Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | FARXIGA (Dapagliflozin) | COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| AstraZeneca PLC | FASENRA (Benralizumab) - (TERRANOVA) | COPD | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | AZD7442 (STORMCHASER) | COVID-19 (post-exposure prophylaxis) | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | Selumetinib - (ASTRA) | Thyroid cancer | Phase 3 | Trial Discontinued | Oral | Oncology |
| AstraZeneca PLC | Tralokinumab (STRATOS1) | Severe, uncontrolled asthma | Phase 3 | Trial Discontinued | Subcutaneous | Respiratory |
| AstraZeneca PLC | Sipavibart (AZD3152) - (SUPERNOVA) | COVID‚Äë19 | Phase 3 | Data Released | Intravenous | COVID-19 |
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (NEPTUNE) | Lung cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | IMFINZI (Durvalumab) +/- tremelimumab - (MYSTIC) | Lung cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
